SOD2 and breast carcinoma: SOD2 has been demonstrated to be targeted by miR‐335,23 supporting our hypothesis that miR‐335 serves as a “bridge” to combine ZNF‐148 and SOD2 in breast cancer cells, and we demonstrated that a ZNF‐148/miR‐335/SOD2 pathway exists in breast cancer.